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1. Introduction 
Approximately 1% of all malignancies or 10,000 cases diagnosed in North American are 
sarcomas. Amongst which, soft tissue sarcoma comprises of the majority. Local disease is 
managed with the use of pre-operative or post-operative radiation and surgery, yielding 
over 90% local control rate.1  In the meta-analysis reported by Figueredo et al.,2 adjuvant 
chemotherapy yielded an absolute overall survival benefit of 4% and the benefit was mainly 
observed in tumours in the extremity, at a deep location, larger than 5 cm or high 
histological grade. Unfortunately, a recently reported adjuvant trial comparing 
doxorubicin/ifosfamide combination with observation enrolling patients with such features 
failed to demonstrate any overall survival benefit.3 
Upon follow-up, 50% of localized soft tissue sarcomas will recur either locally, or 
systemically or both. The benefit of systemic therapy in the recurrent and/or metastatic 
setting, including doxorubicin, ifsofamide and DTIC, has been shown to be modest with an 
overall response rate of 10-15%, as single agent, and of 30% in combination at the expense of 
toxicity without any improvement to the median overall survival rate of 12 months.4  
In the past 10 years, the most significant advancement has been observed in gastrointestinal 
stromal sarcoma (GIST), a rare form of gastrointestinal (GI) tract sarcoma. GIST originates 
from the interstitial cell of Cajal, a pacemaker cell in the muscularis mucosa of the GI tract.5,6 
It is characterized by the expression of CD117 or c-KIT. Eighty-five to 90% of GIST harbour 
activating mutation in c-KIT, predominantly at exon 11 (70-75%), followed by exon 9 (10%) 
and rarely exons 13 and 17 (1-2%). About 5-10% of GISTs have platelet derived growth 
factor receptor-ǂ mutation, predominantly in exons 12 and 18.7-11  The rest harbour mutation 
in neither tyrosine kinase receptors are considered as wild type.7,11,12  Imatinib, a tyrosine 
kinase inhibitor targeting both wild type and mutated c-KIT and PDGFR, as well as ABL 
kinase and BCR-ABL, was the first therapy licensed in metastatic GIST with or without 
mutations in C-KIT and PDGFR with an impressive improvement in response (80% 
response rate as compared to no response for conventional chemotherapy) and a median 
progression-free survival (PFS) of 2-2.5 years and overall survival (OS) of almost 5 years.13-16  
More recently, imatinib has been licensed as adjuvant therapy for resected GIST more than 3 
cm for 1 year with an improvement in progression-free survival.17  In the annual meeting of 
the American Society of Clinical Oncology Meeting in 2011, GISTs with c-KIT expression 
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and either over 10 cm in diameter or >10 mitotic figures per 50 high power fields were 
randomized to 1 versus 3 years of adjuvant imatinib treatment. There was not only an 
improvement in 5-year recurrence-free survival (47.9% versus 65.6%, HR=0.46 and p<0.001) 
but OS (81.7% versus 92%, HR=0.45, p=0.019).18 Upon failure of imatinib, sunitinib has been 
shown in a randomized controlled trial to improve the median PFS as compared to placebo 
(24.1 weeks versis 6 weeks, HR=0.33).19  Unfortunately, recent trials with a more potent c-
KIT and PDGFR-ǂ inhibitor, nilotinib, as compared to imatinib in the first-line and as 
compared to best supportive care in the previously pretreated population failed to provide 
any PFS or OS benefit.  
One of the most important barriers for the management of soft tissue sarcomas is that there 
are more than 50 histological subtypes with diverse clinical, biological and molecular 
characteristics. At the molecular level, soft tissue sarcomas can be divided into 2 categories: 
those with a characteristic chromosomal translocation as in Table 120-22 and those with 
complex karyotypes, including liposarcomas, except for mxyoid/round cell liposarcoma, 
leiomyosarcoma, malignant nerve sheath tumours, etc. Over the years, significant gain in 
the knowledge through translational research in soft tissues sarcoma help identifying novel 
targets for all subtypes or specific subtypes, which has been reflected in design of recent 
trials in this population.23  One would hope therapeutic strategies based on molecular or 
biological characteristic will yield an improvement in the overall survival of patients with 
metastatic soft tissue sarcomas and possibly in the curative setting.  
Despite the impressive improvement in the management and outcome of GIST, resistance to 
imatinib and sunitinib occurs. Through ongoing translational research, secondary resistance 
mechanisms, including secondary mutations in c-KIT or PDGFR-ǂ or activation of 
downstream pathways, have been partially elucidated, which will help developing novel 
agents alone or in combination with imatinib and/or sunitinib.24   
In this chapter, we will focus on the biology of selected targets in soft tissue sarcomas, and 
their current development in all or certain subtypes of soft tissue sarcomas. 
2. Growth signalling pathway 
Insulin Growth Factor Receptor (IGF-R)/PI3 Kinase (PI3K)/mTOR pathway 
Insulin Growth Factor Receptor and Insulin Receptor 
The insulin growth factor pathway consists of 3 ligands, IGF-1, IGF-2 and insulin, IGF 
binding proteins, and 4 receptors, IGF-1R, IGF-2R, insulin receptor (IR) and hybrid IGF-
1R/IR.25-27   
IGF-1R is a transmembrane receptor tyrosine kinase that comprised of 2 ǂ and 2 ǃ subunits. 
Upon binding of ligands, with the highest affinity for IGF-1, followed by IGF-2 and the least 
for insulin, the tyrosine residues in the intracellular domain will be autophosphorylated 
leading to activation of downstream signalling Raf/MAPK/ERK and c-Raf proliferation 
pathways and the PI3K/Akt/mTOR survival pathway.26-28 Structurally, IGF-1R and IR 
share 84% homology in the intracellular domain and 100% in the ATP-binding domain, 
which permits heterodimeration of IGF-1R and IR. 26-28 Complicating by the fact that IR 
exists in 2 isoforms, IR-A or fetal IR which is overexpressed in cancer, and IR-B which is 
present in normal tissues. The 2 isoforms differ by 12 amino acids in exon 11.29  The IR-A 
isoform has high affinity for IGF-2 and insulin but less so for IGF-1.30-32  In the contrary, IGF-
2R is a mannose-6-phophate receptor devoid of any ATP-binding domain, making it a dead 
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receptor which can modulate the growth stimulation activity of IGF-1R and IR through 
binding and internalization of IGF-2.32 
At least six different IGFBPs have been identified, which modulate the plasma 
concentrations of IGF-1 and IGF-2, thus the activation of the receptors in this pathway.25-27   
Various mechanisms of aberrancy of this pathway have been identified and summarized in 
Table 2. In short, the fusion protein from the translocation-associated sarcomas binds to 
either the IGF-233-36 or IGF-1R promoter,37-40 leading to pathway activation. Whereas, for 
those soft tissue sarcomas that harbour complex karyotypes, the pathway is activated 
through overexpression of ligands, IGF-2,36,41,42 IGF-1,42 overexpression of IGF-1R and IR,36 
activation of downstream PI3K/AKT/mTOR pathway.43,44 
Pediatric GISTs are less common to have mutation in c-KIT and PDGFR-ǂ. Agaram et al.45 
and others reported that as compared to wild-type (WT) GISTs in adult, the transcriptome of 
WT pediatric GISTs have an increased expression in IGF-1R without amplification.46,47  
However Tarn et al. reported either overexpression or amplification of IGF-1R in adult WT 
GISTs.48  IGF1-R expression was found to be increased in all 188 patient derived samples 
with at least moderate expression of IGF1/2 in 115 samples. Elevated IGF-1 or IGF-2 
expression is associated with increased mitotic rate and high risk for relapsed in resected 
samples and elevated IGF-1 level is also found to be related to increased risk for metastatic 
disease and relapsed disease in the metastatic setting.49  Inhibition of IGF1-R by a tyrosine 
kinase inhibitor leads to apoptosis via the inhibition of the AKT and MAPK.48  Synergistic 
anti-tumor activity is observed when an IGF-1R tyrosine kinase inhibitor is combined with 
imatinib. Therefore, targeting IGF-1R with or without imatinib is of interest in metastatic 
WT GISTs.  
Currently, there are three different strategies targeting this pathway.  
1. Antibody to IGF-1R was the first therapeutic strategy that entered the clinical and 
current clinical development in sarcoma was summarized in Table 3. These antibodies 
block the binding of IGF-1 and possibly IGF-2 to IGF-1R. The antibody/IGF-1R 
complexes will be internalized and then degraded by the proteosome pathway, leading 
to downregulation of IGF-1R. It has been reported that the activity of these antibody 
depends on the level of membrane IGF-1R expression.50  A number of phase 2 studies in 
soft tissue sarcomas have been reported and stable disease as best response was the 
most common.51,52 Toxicities include hyperglycemia, headache, skin rash and transient 
AST/ALT elevation.  
2. ATP-mimetic, competitive tyrosine kinase inhibitor which inhibits the activation of IGF-
1R homodimer, IR homodimer and IGF-1R/IR heterdimers through IGF-1, IGF-2 and 
insulin. OSI-906, BMS-754807 and XL-288 are currently in phase I clinical development. 
To date, no clinical studies in soft tissue sarcomas have been reported.  
3. Antibody binds to IGF-1 and IGF-2 leading to inactivation of IGF-1R and hybrid 
IR/IGF-1R, while sparing the binding of insulin to IR-B, resulting in the absence of 
hyperglycemia. Recently, a phase I study of MEDI-573 was reported and no 
hyperglycemia was observed and no response was observed.53 
Preclinical studies suggested the level of IGF-1R expression may be a biomarker for 
clinically efficacy for these antibodies, clinical confirmation remains to be reported. Thus far, 
there has been no biomarker for response to small molecule reported. Anti-tumour activity 
in soft tissue sarcoma by targeting the IGF-1R/IR pathway through IGF-1R antibody has 
been modest. This is possibly related to the fact that most soft tissue sarcoma subtypes have 
upregulation of IGF-2, which signals through the IGF-1R/IR-A hybrid receptor and is not 
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blocked by IGF-1R antibody.33,34,36,41  Furthermore, some of the soft tissue sarcoma subtypes 
have pTEN loss, increase in PI3K/Akt mRNA level or activation of IRS-2, circumventing the 
blockade by the antibody upstream.36,41-44  Last but not least, there has been no direct 
comparison in clinical efficacy amongst these three therapeutic approaches.  
PI3K/Akt/mTOR pathway 
Growth factor receptor tyrosine kinases activation will lead to recruitment and activation of 
PI3K to the cytoplasmic side of the cell membrane, which in turn phosphyorylates 
phosphatidylinositol-4,5-phosphate to phosphatidylinositol-3,4,5-phosphate (PIP3). PIP3 is 
dephosphorylated and inactivated by pTEN, and activates Akt through recruitment to the 
cell membrane, which in turn activates mTOR-1 directly and indirectly through inhibition of 
negative regulator of mTOR-1, tubuerus sclerosis complex 2. In mammalian cells, there are 2 
mTOR complexes, mTOR-1, which is rapalogue sensitive, and mTOR-2, which is rapalogue 
insensitive. Recently, mTOR-2 is found to activate Akt, leading to mTOR-1 activation.54,55   
The PI3K/Akt/mTOR pathway is an ideal anti-cancer target, including soft tissue sarcomas, 
as it is activated by all the growth factor receptor tyrosine kinases, such as IGF-1R, VEGFR, 
PDGFR, or by the loss of pTEN or upregulation of PI3K/Akt.41,43,44  In turn, the pathway 
will lead to cell survival and anti-apoptosis through Akt and to cell growth, proliferation, 
metastasis and angiogenesis through activation of S6-kinase and p70. Preclinical study by 
Friedrichs et al. reported activation of PI3K/Akt/mTOR in synovial sarcoma cell lines and 
inhibition of mTOR or PI3K led to tumour regression.56 Similarly, inhibition of mTOR by 
rapamycin led to p53-dependent apoptosis of rhabdomyosarcoma cell lines.57  Wan et al. 
found that this is due to inhibition of the mTOR/HIF-1ǂ/VEGF pathway via S6 kinase.58     
Sapi et al. reported a differential activation of mTOR-1 among 108 cases with GIST with c-
KIT, PDGFR-ǂ and WT mutations (38.4% versus 83.3% versus 73.9%, respectively).59  In 
imatinib-resistant GIST cell lines, despite treatment with imatinib, there is continual 
hyperactivation of c-KIT with no increase in total c-KIT exprerssion. Either PI3 kinase, MEK 
or mTOR inhibition leads to decrease in growth, but only PI3 kinase inhibition led to 
apoptosis.60  Similarly, prolonged treatment with sunitinib leads to silencing of pTEN 
expression through methylation, which in turn leads to activation of the PI3K/AKT 
pathway.61  Ikezoe et al. demonstrated synergism of suntinib with PI3K or mTOR in 
imatinib-resistant GIST.62   
There are currently 3 rapamycin-analogues targeting mTOR-1, temsirolimus, everolimus 
and ridaforolimus, being developed in the clinics. Only temsirolimus (CCI-779) and 
ridoforolimus (AP 23573) have been tested in soft tissue sarcomas. Okuno et al.63  reported a 
phase II study of temsirolimus in metastatic soft tissue sarcoma patients and 22% had prior 
chemotherapy. Two out of 40 evaluable patients attained a partial response for 3 and 17 
months, respectively. But disappointingly, the median time-to-progression (TTP) was only 2 
months or 6-month progression-free rate (PFR) was only 14%, which is deemed to be 
inactive according to the EORTC criteria.64  The median survival was 7.6 months.  
A phase II study of ridaforolimus in osteosarcoma, leiomyosarcoma, liposarcoma and other 
soft tissue sarcomas was reported in abstract form. 93% of patients had prior chemotherapy. 
The primary endpoint was clinical benefit rate at 16 weeks, which were 30% (4 partial 
response), 33%, 30% and 23%, respectively and were deemed active by the authors. The 
corresponding 6-month PFR were 23%, 22%, 25% and 23%. The median overall survival of 
the entire population was 40.1 weeks (range 37.9-44.1 weeks).65   
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In 2011, the phase III study of ridaforolimus versus placebo as a maintenance therapy after 
first to third-line therapy in the metastatic settings for soft tissue and bone sarcomas was 
reported with progression free survival (PFS) as the primary endpoint and overall survival 
(OS) as the main secondary endpoint. In the overall population, the PFS and OS was 
improved from 14.6 weeks to 17.7 weeks in the ridaforolimus treated patients (HR=0.72, 
p<0.0001) and from 19.2 months to 21.4 months (HR=0.88, p=0.22) after first analysis. 
Subgroup analysis including histology, number of prior lines of therapy, etc is pending.66   
A combined phase I/II study combining everolimus and imatinib in pretreated metastatic 
GIST patients was reported. The recommended phase II dose of the combination was 2.5 mg 
daily of everolimus in combination with 600 mg daily of imatinib, denoting 
pharmacokinetic interaction. Two strata were enrolled:  stratum 1 failed imatinib alone and 
stratum 2 failed imatinib and other therapies. A 37% progression free rate was observed in 
stratum 2 with a corresponding PFS and OS at 3.5 and 10.7 months, respectively.67  This 
combination was suggested by the authors to take forward for further development. The 
biological activity seen may be related to the silencing of pTEN as reported by Yang and 
colleagues after treatment with sunitinib.61  Unfortunately, no biopsy samples were 
available in this trial to further elucidate the biology underlying this combination in this 
heavily-pretreated GIST population. 
Toxicities of rapalogues are considered as tolerable with <10% patients experienced grade 3 
or 4 toxicities. Common toxicities include stomatitis, hyperglycemia, hyperlipidemia, fatigue 
and thrombocytopenia.  
In summary, the clinical efficacy of rapalogues in sarcomas has been modest, which may be 
explained by the following resistance mechanisms. Wan et al. reported inhibition of mTOR 
by rapalogues led to the loss of the negative feedback of S6 kinase on IRS-1, leading to 
activation of pAKT.68 Cao et al.69 found that after initial inhibition of IGF-1R and Akt 
phosphorylation by IGF-1R antibody, at 72 hours such inhibition was lost through 
mechanisms independent to pTEN loss or activation of epidermal growth factor. The 
activation of the Ras/Raf/MEK/Erk pathway led to inhibition of mTOR leading to loss of 
addiction to the IGF pathway.70,71 
To circumvent these resistance mechanisms, phase I/II studies of combined PI3K/mTOR 
inhibitors such as BEZ235, IGF-1R-mTOR and Akt-MEK (MK-2206 and AZD 6244) 
combinations in solid tumours are currently being performed. The improvements in clinical 
efficacy in soft tissue sarcomas remain to be reported.  
Complicating the development of rapalogues is the lack of biomarkers. Despite pTEN loss 
leads to constitutional activation of mTOR, pTEN status did not predict clinical benefit.72  
Similarly, inhibition of S6 kinase and p70 activation did not predict clinical benefits.  
Targeting Akt or PI3K upstream from mTOR may offer an alternative strategy in the 
treatment of soft tissue sarcomas. Barrentina et al.73 reported 18% of mxyoid/round cell 
liposarcoma had PIK3CA mutation leading to Akt activation, which is associated with poor 
survival. Zhu et al.74 found activation of PI3K and Akt in all the soft tissue sarcoma cell 
lines. Inhibition of PI3K or Akt led to inhibition of downstream pathway, leading to cycle 
cell arrest at G2 phase through upregulation of GADD45ǂ. Activation of Akt and mTOR 
was observed in 61% and 66% of the 140 sarcoma samples, particularly in malignant nerve 
sheath tumours, rhabdomyosarcoma and synovial sarcoma, independent from EGFR 
activation. Phosphorylation of Akt was associated with metastatic disease.75   
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Inhibition of both PI3K and mTOR by BEZ235 leads to G1 phase cell cycle arrest without 
apoptosis in both in vitro and in vivo sarcoma models including Ewing’s and 
rhabdomyosarcoma. As a single agent, no apoptosis was observed. But synergistic anti-
tumour effect was observed when BEZ235 is combined with classical active 
chemotherapeutic agents in sarcoma, including doxorubicin, when chemotherapy is given 
first. Simultaneous targeting with IGF-1R showed synergistic activity probably due to 
decrease in IC50 for PI3K inhibition by BEZ235.76  Therefore, clinical studies of PI3K 
inhibitor in mxyoid/round cell  liposarcoma and  of PI3K or Akt inhibitors in malignant 
nerve sheath tumour, rhabdomyosarcoma and synovial sarcoma may be of value.  
As mentioned previously, PI3K inhibition with concurrent imatinib not only leads to growth 
inhibition but also apoptosis in imatinib-resistant GIST cell lines as compared to mTOR 
inhibition. Therefore, clinical investigation of PI3K inhibitor in combination with imatinib in 
imatinib failure GIST patients may be of value. Similarly, the activation of 
PI3K/AKT/mTOR due to methylation of pTEN from prolonged sunitinib treatment can be 
exploited as a novel therapeutic option for sunitinib failure.  
3. Vascular endothelial growth factors, fibroblast growth factors and 
receptors 
Angiogenesis is a complex biological process involved in the formation of new blood vessels 
in normal and pathological tissues, including cancer.77,78  A battery of proangiogenic and 
antiangiogenic factors is involved in angiogenesis, which is tightly controlled in normal 
tissues, but not in pathological processes including cancer.77,78 In cancer, angiogenesis is a 
result from the interaction of various proangiogenic and antiangiogenic factors and their 
receptor produced or present in tumour cells, endothelial cells, extracellular matrix and 
inflammatory cells.79 
A number of proangiogenic and antiangiogenic factors have been identified (Table 3). The 
most important proangiogenic factor is vascular endothelial factor (VEGF) which is present 
in six isoforms, VEGF A to E and placental growth factor (PIGF).80  Furthermore, VEGFA 
exists as 6 proangiogenic isoforms (VEGF 121, 145, 148, 165, 183, 189 and 206) and 6 
corresponding antiangiogenic isoforms, generated through alternative splicing of exons 6, 7 
and 9 of VEGFA gene.79,81   
There are a total of 4 VEGFR, namely VEGFR-1, VEGFR-2, VEGFR-3 and VEGFR-4. 
Interaction of VEGFR-2 and its ligands, VEGFA and PIGF, represents the most important 
angiogenic pathway. Whereas, VEGFA, VEGF-B and PIGF bind to VEGFR-1 for 
angiogenesis and VEGF-C and D bind to VEGFR-3 for lymphogenesis.80   
Increasing level of angiogenesis or elevation of VEGF expression in soft tissue sarcoma 
samples has been reported to be associated with high grade, increase risk of metastases and 
poor prognosis.82-84  Serum VEGF expression is elevated in all soft tissue sarcomas85-87 
especially epithelial subtypes including epithelioid sarcoma and alveolar soft part sarcoma 
(ASPS),88 and high grade fibrosarcoma of no specific subtype (previously known as 
malignant fibrous histiocytoma) and leiomyosarcoma.89  In addition, VEGF A, B and C and 
their corresponding VEGFR-1, -2 and -3 are overexpressed in angiosarcoma, demonstrating 
an autocrine or paracrine growth pathway, with corresponding activation of the 
PI3K/Akt/mTOR pathway.90-92  Antonescu et al. also demonstrated overexpression of TIE-
2, VEGFR-1 and -2 in angiosarcoma, and 10% of the samples demonstrated mutations in 
either exon 15 in the extracellular domain and exon 16 in the transmembrane domain.93  
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Thus, targeting VEGFs and their receptors is an attractive strategy for the treatment of soft 
tissue sarcomas, especially angiosarcoma, and ASPS.  
Targeting VEGF can be achieved through 
1. Monoclonal antibody to VEGF-A by Bevacizumab: A phase II study combining 7.5 
mg/kg of bevacizumab with standard dose doxorubicin at 75 mg/m2 every 3 weeks in 
patients with metastatic soft tissue sarcomas was reported D’Adamo et al. 17 patients 
were treated and only 2 PRs were observed with a median time-to-progression and 
median overall survival of 8 and 16 months, respectively. Despite dexrazoxane, 6 
patients experienced at least grade 2 congestive heart failure, making it too toxic for 
further development of the combination.94  Bevacizumab at 15 mg/kg every 3 weeks 
was tested in a phase II study of patients with metastatic angiosarcoma and epithelioid 
hemagioendothelioma. 29 patients were enrolled and out of 26 evaluable patients, 3 PRs 
were observed. Currently, the development of bevacizumab is unclear despite this level 
of activity in angiosarcoma.95  Common toxicities include hypertension, macular or 
papular erythematous rash, diarrhea, mucosal bleeding (most common as epitaxis) and 
proteinuria. Other rare toxicities are hemorrhage, hypertensive emergency and 
reversible posterior leukoencephalopathy syndrome, arterial thromoembolism 
(especially in patients over 65 years), bowel perforation and fistulae. 
2. Aflibercept is a decoy recombinant protein of the second Ig domain of VEGFR-1 and 
third Ig domain of VEGFR-2 fused to the Tc domain of human IgG1, with pM affinity to 
VEGF-A, -B and PIGF. In vivo rhbadomyosarcoma model treated with aflibercept at 2.5 
mg/kg twice weekly demonstrated significant anti-tumour activity.96,97  Late stage 
clinical development in metastatic non-small cell lung cancer, colorectal cancer and 
other solid tumours are either ongoing or reported. But no development plan in soft 
tissue sarcoma has been made. Toxicities are consistent with other anti-VEGF/VEGFR 
agents, such as hypertension, headache, proteinuria, fatigue, dysphonia, bleeding 
(epistaxis and hemoptysis), anorexia, abdominal pain, nausea, diarrhea or constipation, 
and arthalgia.  
3. Small molecules ATP-mimetic receptor tyrosine kinase inhibitors:  VEGFR is a member 
of the split kinase class III receptor which shares structural homology in the ATP 
binding domain with platelet derived growth factor (PDGFR), FLT-3, c-kit, and Tie-2. 
Although in preclinical models, co-inhibition of PDGFR and VEGFR may yield 
synergistic anti-tumour activity through targeting of the endothelial cells and pericytes 
in the tumour vasculature, resepctively and delay in tumour resistance,98-102 additional 
toxicities are expected. Additional receptor tyrosine kinases are inhibited by some of 
these small molecules at clinically relevant plasma concentration, such as RET in 
motesanib, vandatinib, FGFR-1, 2 or 3 in BIBF 1120 and brivanib103,104 and c-met in 
foretinib, cabozantinib and MGCD265,105 leading to possible synergistic anti-tumour 
activity.  
The early phase development of sunitinib,106,107 sorafenib108-111 and pazopanib112 in various 
types of soft tissue sarcomas is summarized in Table 4. With the observed progression-free 
survival benefit in the phase II trial of pazopanib across all soft tissue sarcoma subtypes, a 
phase III trial comparing pazopanib and placebo in metastatic soft tissue sarcoma was 
reported in the 2011 annual meeting of the American Society of Clinical Oncology with 
progression-free survival as the primary endpoint. Patients had prior anthracyclin but had 
no more than 4 prior lines of therapy, and performance status of 0-1. With a median follow-
up of 15 months, and 19% of patients still on study, the median progression-free survival in 
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the pazopanib treated patients was improved from 1.5 to 4.6 months (p<0.0001). The interim 
median overall survival was 11.9 versus 10.4 months (p>0.05), favouring the pazopanib 
arm.113   
Based on the success of sunitinib as second-line therapy for metastatic GIST, other 
antiangioenic compounds have been in clinical development in pretreated GIST. Campbell 
et al. reported a phase II study of sorefenib in imatinib- and sunitinib-pretreated metastatic 
GIST patients. An impressive 13% response rate was observed with median PFS at 5.2 
months and OS at 11.6 months which were compared to that of sunitinib.114  In the annual 
meeting of the American Society of Clinical Oncology Meeting in 2011, the final result of a 
phase II study of regorafenib in pretreated GIST was reported. Regorafenib is a multi-
targeted tyrosine kinase inhibitor targeting VEGFR 1-3, TIE2, PDGFR-ǃ, FGFR-1, as well as 
B-RAF, C-RAF and p38 MAPK at nanomolar concentration. Three PRs and a median PFS of 
10 months were observed for the entire population. Due to the small patient numbers, 
median PFS were 10, 6 and 8 months for those harboured exon 11, 9 and WT c-KIT mutation 
respectively. Interesting, one patient was found to have B-RAF mutation in exon 15.115  
Agaram et al. reported up to 7% of WT GIST had V600E mutation in B-RAF.116  In preclinical 
models, sorafenib has superior inhibitory activity in secondary mutations in the activation 
loop, such as D816H, D820A/G, V822K, and Y823D, of c-KIT as that of sunitinib, and similar 
activity towards ATP pocket secondary mutations, such as V654A and T670I, and exon 9 c-
kit mutations.117  Sorafenib, most likely regorafenib, inhibits cell proliferation, induces 
apoptosis and decreases angiogenesis through the inhibition of Ras/Raf/MEK/ERK 
pathway as well as induction of p15 and p27 and decrease in p21, cyclin A and B1 as well as 
cdc-2.118  Based on these biological rationales, sorafenib and regorafenib will expect to have 
substantial clinical activity in GIST. A phase III study of regorafenib in the imatinib- and 
sunitinib-pretreated metastatic GIST patients has just finished enrollment.  
The VEGF and FGF pathways are associated with growth and poor prognosis in soft tissue 
sarcomas.119  Upregulation of other proangiogenic pathways, such as the FGF pathway, has 
been conferred as resistance mechanism for anti-VEGF strategies.120  Tumour growth 
suppression has been observed in preclinical soft tissue sarcoma xenografts by FGF 
inhibition.121  Therefore, combined FGFR and VEGFR tyrosine kinase inhibitors may have 
improved anti-tumour activity and duration of response in soft tissue sarcomas. In a 
retrospective analysis of 43 solid tumour samples through a phase I study of brivanib, 
expression of FGF-2 was associated with longer progression-free survival and higher disease 
control rate.122 Schwartz et al. reported the preliminary result of a randomized 
discontinuation study of brivanib in metastatic soft tissue sarcomas to detect an HR of 0.5 in 
progression free survival in the FGF-2 positive patients. 251 patinets were enrolled with a 
median age of 54, and all patients were ECOG 0-1 and 80% had prior systemic therapy with 
a median of 2 regimens. During the first 12 weeks of open label brivanib, 130 patients had 
PD and 35 patients were taken off study due to reasons other than PD. Seven patients had a 
PR, and 3 were either angiosarcoma or hemangiopericytoma. Out of the 78 patients who had 
SD and underwent randomization to brivanib or placebo, 53 patients had FGF-2 positive 
tumours, and the median progression-free survival was 2.8 months in the brivanib arm as 
compared to 1.4 months in the placebo arm (HR=0.58, p=0.08). The progression-free rate at 
12 weeks in the overall population was 31% and no difference was observed across all 
histological subtypes. In the FGF-2 negative tumours, the corresponding progression-free 
survival was 2.6 and 1.4 months (HR=0.8). The median progression-free survival was 4.1 
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months in those in the placebo arm who crossed over to brivanib at progression. Brivanib 
was considered as well tolerated. All grade 3 or higher toxicities occurred in less than 5% 
except for fatigue (10%) and hypertension (15%).123   
Clinical benefit with tyrosine kinase inhibitors observed in angiosarcoma is particularly of 
interests as clinical response with classical chemotherapy, such as doxorubicin, liposomal 
doxorubicin and paclitaxel, is usually short-lived.108-110  Various reports have demonstrated 
overexpression of VEGFR-2 and VEGFR-3 and their corresponding ligands, VEGF-A, VEGF-
C, in pulmonary and cutaneous angiosarcomas, denoting the paracrine and/or autocrine 
role in their development and proliferation.90,124,125   
Alveolar soft part sarcoma (ASPS) is known to be chemotherapy resistant and therefore 
development of novel agents is essential. Stacchioti et al.126 reported a series of 10 patients. 
Five patients had prolonged PR and 3 other had prolonged stable disease, with a median 
duration of response of more than 9 months. Similar impressive clinical benefit of 4 out of 7 
patients had a PR and 3 patients with SD by RECISTS were reported for cediranib.127  The 
investigators in the National Cancer Institute reported the preliminary results of a phase II 
study of cediranib with 14 PRs in 33 untreated or second-line metastatic ASPS patients. 
Biopsies for gene expression profile alterations were performed before and after treatment 
and VEGFR-1, VEGFR-2 and angiopoietin-2 expression were downregulated whereas 
CXCR7, CCL-2 and transgelin were upregulated.128  Currently, a cross-over phase II trials 
comparing cedarinib and sunitinib is being planned. The transcription factor activity of the 
ASPACR1-TFE3 chromosomal translocation leads to overexpression of growth factor 
receptors, including VEGFR-2, PDGFR, c-Met, RET and EGFR, and  transcription factor, 
HIF-1ǂ. The activation of these pathways leads to activation of both the PI3K/Akt/mTOR 
and ERK pathway.126,129-131   
4. Monoclonal antibody to the extracellular domain of VEGFRs or PDGFR:  IMC1121B 
(ramucirumab) and IMC18F-1, targeting the VEGFR-2 and VEGFR-1 extracellular 
domain respectively, are currently under clinical development as a single agent or in 
combination with chemotherapy in other solid tumours. IMC-3G3, a monoclonal 
antibody against the extracellular domain of PDGFR, is currently in clinical 
development including in PDGFR mutated metastatic GIST.  
The preliminary phase II and III trial result in antiangiogenic compounds look promising in 
all soft tissue sarcomas, especially for angiosarcoma, hemangiopericytoma, ASPS, which 
devoid of effective systemic therapy. Further development of this class of agent in these 
uncommon subtypes is definitely worthwhile. Given the activation of multiple growth 
factor pathways, like VEGFR, PDGFR, Tie-2, the use of tyrosine kinase inhibitor may be 
more likely to provide clinical benefit, unlike that in other solid tumours. With the activation 
of downsteam pathways, including the PI3K/Akt/mTOR or MEK/ERK pathway, 
combination with antiangiogenic strategy, especially for tyrosine kinase inhibitors, may be 
at least additive. Furthermore, combinations with doxorubicin and other cytotoxic 
chemotherapy will be reported in the next couple of years, which have the potential of 
improving their anti-tumour activity. Like the identification of FGF-2 expression as a 
potential biomarker for efficacy for brivanib, further exploration for biomarker for 
antiangiogenic therapeutics is important which allows us to identify the corresponding 
patient subgroups and to improve the understand of the biology of angiogenesis and thus 
the mechanisms of resistance and corresponding therapeutic strategies.  
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4. Epigenetic modification and histone deactylase inhibitors 
Histones and histone deactylase  
There are 5 members of the histone family, H1, H2A, H2B, H3 and H4 in eukaryotic cells. 
Tetramer of H3 and H4 and dimmers of H2A and H2B make up nucelosomes, around which 
DNA winds. H1 makes this complex more compact. The amino terminal of histones 
undergoes post-translational modification by acetylation, phsophorylation and methylation, 
leading to change in the structure and function of the histones. Acetylation and 
deacetylation are the most  studied processes. The lysine residues in histones, particularly 
H3 and H4, undergo acetylation by histone acetyltransferase (HAT) and deacetylation by 
histone deacetylation (HDAC) which determine the fate of gene expression.132  Acetylation 
leads to neutralization of the positive charges in the lysine residues of H3, decrease in the 
affinity to DNA, and thus generating an open or euchromatin structure which allows the 
binding of transcription factors. Conversely, deacetylation leads to tight interaction between 
the histones and DNA, generating a closed or heterochromatin structure which prevents 
gene transcription. 132,133  
There are 4 classes of HDAC: Class I includes HDAC 1, 2, 3, and 8 and is ubiquitously 
present in the nucleus; Class II includes Class IIa (HDAC 4, 5, 6 and 7) and Class IIb (9 and 
10), which shuttles between the cytoplasm and nucleus and is tissue specific, Class III 
includes SIRT 1-7 and is NAD+ dependent for its activity and Class IV includes HDAC 11 
and properties of Classes I and II.134-136  Classes I, II and IV are homologous in their structure 
with a zinc-containing catalytic domain.  
Recently, HDAC Classes II is found to modulate acetylation status of proteins, such as heat 
short protein 90 (Hsp 90). Acetylation of Hsp 90 leads to release of oncoproteins, such as 
Her-2, Akt, c-kit, bcr-Abl, and subsequently subject to proteosome-mediated degradation.135 
This process is believed to account for at least a good portion of the anti-tumour activity of 
HDAC inhibitors. Specifically, inhibition of HDAC 6 and 10 leads to downregulation of 
VEGFR1 and 2 expression through acetylation of Hsp90.137 Other members of Class II 
HDAC are involved in either cell proliferation and survival or cell migration, which is 
crucial for angiogenesis.138,139 
Histone deacetylase and sarcoma 
Overexpression of one or more members of Class I and II HDAC has been well reported 
in breast, prostate and colorectal cancer,135 which has not been reported in soft tissue 
sarcoma.  
Preclinical studies of HDAC inhibitors demonstrated not only tumour growth suppression 
but also tumour regression and differentiation in human synovial sarcoma xenografts.140,141  
Synovial sarcoma is characterized by the expression of oncoprotein, STY-SSX, which co-
localizes with the Polycomb repressor complex leading to HDAC-mediated chromatin 
condensation.142-144 In particular, the interaction among the Polycomb protein, the SS18 
component of the oncoprotein and a transcriptional corepressor protein called TLE was 
observed.145 One of the repression targets of this complex is the tumor suppressor gene 
EGR1.146  HDAC inhibitor will reverse the repression by the Polycomb protein, leading to 
de-repression of EGR1 and followed by apoptosis.  
Similar preclinical anti-tumour effect has been observed in Ewing sarcoma,147-149 clear cell 
sarcoma,150 endometrial stromal sarcoma,151 mxyoid chondrosarcoma152 and alveolar 
rhabdomyosarcoma.149  Treatment of HDAC inhibitor leads to increase in expression of p21 
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and G2/S arrest and decrease in mTOR expression and activity, leading to apoptosis and 
autophagy.151  
In addition, Lopez et al. reported G2/M arrest and S phase depletion of fibrosarcoma, 
leiomyosarcoma and rhabdomyosarcoma cell lines with PCI-24781, a novel HDAC inhibitor, 
followed by decrease in RAD51 and apoptosis.153  Synergistic anti-tumour activity has been 
observed when combining doxorubicin with HDAC inhibitor, when modest anti-tumour 
activity was observed after treatment with doxorubicin or HDAC alone.153,154   
Based on these promising preclinical data, clinical development of HDAC inhibitor in 
translocation associated sarcoma is definitive of interest. Combination with doxorubicin will 
be of interests in both translocation associated sarcomas and in soft tissue sarcomas with 
complex karyotypes. Inhibition of HDACs can lead to at least partial decrease of VEGFR-1 
and -2 and significant clinical efficacy has been observed with VEGFR tyrosine kinase 
inhibitors in patients with ASPS, angiosarcoma, etc, so clinical development of these 
combination will likely provide improved clinical efficacy, with caution about the possibility 
of increase toxicity. Other combinations that may be of interests include HDAC inhibitor 
with therapeutics targeting the PI3K/Akt/mTOR pathway and PARP inhibition.  
Double strand DNA damage due to radiation leads to activation of ATM which 
subsequently activates other downstream DNA repair proteins, including p53, CHK-2, 
BRCA-1, leading to cell cycle delay or apoptosis.155  HDAC1 interacts with ATM which leads 
to its activation and DNA repair.156  HDAC inhibitor is a radiosensitizer through 
suppression of DNA repair by decreasing the expression of DNA repair proteins such as 
DNA protein kinase.157  Therefore, combination of HDAC inhibitor and radiation in the 
management of localized limb or retroperitoneal sarcomas will be worth studying. 
HDAC inhibitors in clinical development 
There are four classes of HDAC inhibitor, short fatty acid, hydroxamic acid, cyclic 
tetrapeptide, and benzamide. Except for the first class, all the others are in clinical 
development. Focus will be placed on the hydroxamic acid and benzamide class of HDAC 
inhibitors. 
Hydroxamic acid analogues 
Vorinostate or suberoylanilide hydroxamic acid (SAHA) is the first orally administered 
HDAC inhibitor in clinical development, which targets Class I, IIa and IIb HDAC. A dose of 
300 mg twice daily 3 days every week or 400 mg daily or 200 mg twice daily.158  It is 
currently licensed for the treatment of cutaneous T-cell lymphoma. The result of vorinostat 
as a second-line therapy in malignant pleural mesothelioma is anticipated in later part of 
2011. Clinical development in combination with chemotherapy in various solid tumours has 
been slow due to toxicity compared to chemotherapy alone. Marked production of reactive 
oxygen species was observed in preclinical model was treated with the combination of 
bortezomib and HDAC inhibitor through suppression by bortezomib on NF-κB production 
induced by HDAC inhibitor, which in turn leads to reactive oxygen species production.159,160 
A phase II study of vorinostat in combination with bortezomib in second-line soft tissue 
sarcoma reported with no response in 16 evaluable  patients.161 
Panobinostat (LBH-589) is another Class I, IIa, and IIb HADC inhibitor in clinical 
development with both oral and intravenous formulation. Dose-limiting toxicity is 
prolonged QTc, thrombocytopenia, neutropenia and hypophosphatemia and diarrhea, 
fatigue and thrombocytopenia for intravenous162 and oral panobinostat,163,164 respectively. 
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Early phase studies of either as a single agent or in combination with chemotherapy and 
novel agents to Hsp 90, Her-2, EGFR, VEGFR, etc are ongoing.  
Belinostat (PDX-101) is again a Class I, IIa, and IIb HDAC inhibitor. An intravenous 
formulation entered clinical development as a daily for 5 day every 3 week schedule. 1000 
mg/m2/day was determined to be the phase II dose. Histone H4 hyperacetylation lasted for 
4-24 hours after each infusion. Best response was SD, and amongst which 2 soft tissue 
sarcoma patients lasted for 7 and 14 months, respectively.165 A preliminary report of 14 
patients using various schedules, daily, twice or three times daily, at doses ranging from 
900-1000 mg/m2/dose and for one day to for 5 days every 21 days.166 Clinical development 
plan of both single agent in various solid tumours and haematological malignancies and 
combination with chemotherapy and demethylating compounds are ongoing including a 
phase I/II trial in combination with doxorubicin in soft tissue sarcoma.  
Other hydroxamic acid analogues are in clinical development including PCI-24781, a Class I, 
IIa and IIb HDAC inhibitor with high potency against HDAC 1 and 3, which is being 
developed in haematological malignancies and solid tumours.167  Based on the synergistic 
anti-tumour effect in combination with doxorubicin, possibly through hyperacetylation of 
topo-II, a phase I/II study is currently recruiting patients.  
Benzamide analogues 
MS-275 was initially developed at the US NCI using various schedules, daily for 4 out of 6 
weeks, once every 2 weeks and weekly for 4 out 6 weeks.168,169 Due to excess toxicity and 
prolonged half-life, only the latter 2 schedules are being developed mostly in combination 
with other protein targets of HDAC class IV.  
MGCD0103 is HDAC 1, 2, 3 and 11 specific HDAC inhibitor. Siu et al.170 reported the phase I 
study using a three times a week schedule with 45 mg/m2/day as the phase II dose. 
Acetylation at H4 increased in a dose-dependent fashion and significantly acetylation in 
white cells was observed at doses above 45 mg/m2/day. No objective response was 
observed except SD in 5 patients for 4 or more months. Currently, development of 
MGCD0103 in concentrated in lymphoma and other haematological malignancies.171   
SB939, a HDAC Class I, II, and IV, has been tested in weekly 3 out 4 weeks and daily for 5 
day every 2 weeks schedules with improved intra-tumour accumulation and transit time, 
HDAC inhibition as well as half-life.172 60 mg a day was determined to be the dose for either 
schedule.173,174  Only SDs for a median of 5 months, as best response, were observed. Proof 
of concept phase II study in translocation associated soft tissue sarcomas led by the NCIC-
CTG is accruing patients.  
Fatigue, nausea, vomiting, diarrhea and anorexia are common to all classes of HDAC 
inhibitors in oral or intravenous formulations. In the absence of comparative trials, cardiac 
toxicity, such as arrhythmia and prolongation of QTc, seems to be occur more frequently in 
the intravenous formulation, which is probably related to the peak concentration of HDAC 
inhibitor is approached the inhibitory concentration of cardiac ion channels. This 
observation may favour the development of oral formulation but careful cardiac monitoring 
will be essential when combined with therapeutics that have been associated with cardiac 
toxicities including HER-2, VEGF/VEGFR. Thrombocytopenia is the only observed 
haematological toxicities, though mostly grade 1 and 2. The mechanism is still being 
investigated.  
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HDAC inhibition in peripheral blood mononuclear cells as a pharmacodynamic marker for 
anti-tumour activity and drug exposure has not been consistent. Identification of such a 
marker is still essential.  
The mechanisms of action of HDAC inhibitor are likely multi-fold and inhibition of different 
classes of HDAC may have different anti-tumour effects.135  Thus clinical activity may be 
different and whether cross-resistance will occur. Fantin et al. reviewed the potential 
mechanisms of resistance for HDAC inhibitors such as increase in DNA hypermethylation, 
upregulation of protection against oxidative stress,  and overexpression of anti-apoptotic 
proteins, such as Bcl-2 and Bcl-XL.175 
5. DNA repair by poly (ADP-ribose) polymerases (PARP)   
Poly (ADP-ribose) polymerases (PARP) 
DNA damage leads to the activation of PARP, which consists of 17 members176,177 that have 
a conserved catalytic domain.178  PARP1 is the most well characterized nuclear protein with 
three functional domains:  the zinc finger containing DNA binding domain, which is 
responsible for the detection of DNA breaks and localization to the nuclei; the auto-
modification domain which includes the breast cancer gene-1 (BRCA-1) C-terminal domain; 
and the C-terminal catalytic domain.179,180  Any single strand DNA break detected by the 
DNA binding domain of PARP1 leads to ADP-ribose polymerization with base excision 
repair proteins, such as XRCC-1, DNA polymerase-ǃ and DNA ligase III, histones and 
PARP1, by the catalytic domain, which is NAD-dependent.181,182 In turn, this complex 
process affect DNA replication, transcription, differentiation, gene regulation, protein 
degradation and mitotic spindle maintenance. Only in the absence of PARP-1, which 
accounts for 90% of PARP activity, PARP2 will be involved in DNA repair.183  
Relevance of PARP and soft tissue sarcomas 
Farmers et al.184 demonstrated homozygous deletion of BRCA-1 or BRCA-2 led to sensitivity 
to PARP1 inhibition, resulting in apoptosis. Apoptosis is postulated to be the loss of 
homologous recombination repair after single strand DNA breaks as a result of both PARP1 
inhibition and loss of BRCA-1 or -2. To date no BRCA-1 or -2 germline loss has been 
documented in soft tissue sarcomas. But Xing et al. reported 29% of uterine leiomyosarcoma 
had decrease or absent BRAC-1 protein expression, which is postulated to be due to 
methylation of BRCA-1 gene promoter.185  Schoffski et al.186 reported decrease in BRCA-1 in 
50% of the soft tissue sarcoma samples.  
In addition, members of the Fanconi family proteins are involved in double strand DNA 
repair through activation of ATM and ATR and formation of a nuclear complex of 5 Fanconi 
family proteins. This complex subsequently co-localizes with BRCA1 and -2 for DNA 
repair.187 Loss of function or expression of any of these protein or “BRCA-ness” confers 
sensitivity to PARP1 inhibition.188 189 ATM is a serine/threonine kinase that activates 
checkpoint kinase -2 (Chk-2) in the presence of DNA damage and sequentially, leads to 
increase in RAD51 and BRCA1 and -2 activity.155 A study of leiomyosarcoma and 
gastrointestinal stromal sarcoma samples showed frequent 13q21-q32 amplification, which 
corresponds to BRCA-2 and RB1 gene location, and 11q22-q24 loss, which contains the ATM 
gene, in high grade and >5 cm leiomyosarcoma. 83% of the samples had either absence or 
weak ATM expression by immunohistochemistry and out of which 50% had 11q loss.190  
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Similarly, loss of ATM was reported in 41% of alveolar rhabdomyosarcoma.191 Concurrent 
ATR loss and K-ras G12D mutation in p53 heterogyous mice developed lung 
adenocarcinoma and sarcomas.192  Germline Chk-2 loss has not been reported in sarcoma 
except in osteosarcoma193, and a variant of Li-Fraumeni syndrome-related malignancies  
RAD51 is transcriptionally controlled by pTEN. Loss of pTEN43 and rarely pTEN 
mutation194,195 has been documented in leiomyosarcoma and uterine leiomyosarcoma, 
respectively and 12% of various soft tissue sarcomas had hypermethylation of the pTEN 
gene.196  Interestingly, only truncated pTEN but not point mutation confers sensitivity to 
PARP1 inhibition.197  Whereas increase in RAD51 expression in soft tissue sarcoma leads to 
resistance to doxorubicin due to S/G2 phase arrest. In the presence of wild type p53 through 
activator protein 2, RAD51 expression was downregulated through decrease in promotor 
activity.198   
PARP inhibitor potentiates chemotherapy and radiation 
Potentiation of preclinical anti-tumour efficacy was observed when combining PARP 
inhibitor with methylating agents (DTIC, temozolamide), alkylating agent 
(cyclophosphamide, ifosfamide), doxorubicin, topoisomerase I inhibitors and platinum 
agents, which are of relevance in soft tissue sarcomas.199-202  Soft tissue sarcomas that have 
low BRCA1 expression had statistically significantly higher response rate, PFR at 6 months, 
and OS to trabectadin, thus, one may suspect that the combination of PARP inhibition with 
trabectadin may confer additive or synergistic anti-tumour activity.  
Radiation is commonly being given pre-operatively or post-operative for localized soft 
tissue sarcomas of the limbs and retroperitonium. Single strand and sometimes double 
strand DNA breaks occur after radiation lead to PARP1 activation followed by DNA repair. 
Similar potentiation of radiation induced anti-tumour efficacy has been observed when 
given with PARP1 inhibitor.199-202   
Thus PARP1 inhibitors either as a single agent or in combination with DNA damaging 
agents and radiation will be worthwhile to explore in soft tissue sarcomas. One may predict 
that single agent activity will be observed only in those soft tissue sarcomas that have a low 
BRCA1 protein expression resulting from promoter methylation or other post-translational 
mechanisms. To select this selected population, immunohistochemistry of BRCA1 and 
BRCA2 will suffice. When use in combination with DNA damaging agents and radiation, 
PARP1 inhibitor will act as a potentiating agent. But one may still expect those tumours 
with a low BRCA1 protein level will have a better response.  
PARP inhibitor in clinical development 
Olaparib (AZD2281; KU-0059436) is a phthalazione class PARP1 and 2 inhibitor. A phase I 
study of 60 solid tumour patients were treated at doses from 100 mg to 600 mg twice daily 
on either a 2 weeks on 1 week off or continuous schedules. Grade 1 or 2 drug-related 
anemia, lymphopenia, fatigue, vomiting dyguesia and anorexia were reported. Dose-
limiting toxicity included grade 3 mood alteration, grade 3 fatigue, grade 3 somnolence and 
grade 4 throbocytopenia were observed in 1 and 2 patients, respectively in the continuous 
schedule at 400 and 600 mg twice daily. As predicted by preclinical data, responses were 
observed in BRCA 2 mutation positive ovarian and breast cancer. One BRCA2 mutation 
positive prostate cancer had 50% reduction of PSA and resolution of bone metastases.203 
Forty percent of BRCA1/2 mutation positive BRCA1/2 mutation positive ovarian cancer 
had a PR or reduction of CA125 for a median of 28 weeks.204   
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AG014699 (PF-01367338) is a PARP1 and 2 inhibitor administered intravenously. Based on 
synergistic preclinical anti-tumour activity with temozolomide, a phase I study was 
reported. The addition of PF-01367338 did not increase temozolomide related toxicity, 
allowing administration of full dose temozolomide at 200 mg/m2/day for 5 days. Increase 
in single strand DNA break was observed only when PF-01367338 was administered 
concurrently with temozolomide. A PR was observed in one melanoma, one pretreated 
desmoids tumour. Stable disease for more than 6 months was observed in 4 patients, 
including one leiomyosarcoma.205   
Adoption of the novel phase 0 design, Kummar et al. found a good correlation of PARP 
inhibition in tumour and peripheral blood mononuclear cells by ABT 888. A minimum of 
50% reduction of PARP activity was observed with 25-50 mg of ABT 888 daily. Due to an 
average 70% of ABT 888 is excreted in urine unchanged during the 24 hours at 50 mg or 
higher daily, continuous dosing will be necessary.206    
BSI-201 was initially thought to be an intravenously administered irreversible PARP1 
inhibitor, but due to recent preclinical and clinical data showed that PARP1 is not inhibited 
at clinically relevant concentration. Thus no further discussion will be presented in this book 
chapter.  
MK-4827 is an orally administered PARP1 and 2 inhibitor. Sandhu et al. reported a phase I 
study of MK-4827 given daily at doses 30-210 mg. Dose-limiting toxicity included grade 3 
fatigue, pneumonitis and anorexia. Common toxicities were all grade 1-2 such as nausea and 
myelosuppression. At doses of 110 mg daily, sustained PARP inhibition was observed in 
peripheral blood mononuclear cells. Responses and SD for more than 16 weeks were 
observed in sporadic and BRCA-related breast or ovarian cancer. One heavily-pretreated 
non-small cell lung cancer patient had SD for more than 42 weeks.207   
A number of other PARP inhibitors are in phase I clinical development, including E7016 
(PARP1 and 2 inhibitor) and CEP-8983 and its prodrug, CEP-9722 (PARP1 and 2 inhibitor).  
Based on the preclinical and translational research information, PARP inhibitor in 
combination with DNA damaging agents (anthracyclin, ifosfamide, DTIC and trabectedin) 
and radiation will be of interest. As reported by Plummer et al., enhanced DNA breaks is 
observed only when PARP inhibitor is administered concurrently with chemotherapy. Thus 
careful preclinical and clinical study of the schedule of these combination should be 
performed not only to enhance anti-tumour activity, but also to reduce unnecessary 
toxicities.  
Development as a single agent may only be applicable to those with low BRCA1 protein 
expression, low ATM expression such as gastrointestinal stromal tumour, leiomyosarcoma 
and alveolar rhabdomyosarcoma and low RAD51 expressing sarcomas.  
Development of resistance is the rule rather than exception for PARP inhibitor. Reversal of 
loss of nonsense mutation in BRCA2 due to a second mutation has been reported.208  Pre- 
and post-treatment biopsies in the setting of localized disease or metastatic disease may 
proven to be valuable in further our understanding of the predictive biomarker for 
response, the biological effect of PAPR inhibitors alone and/or in combination with other 
agents and  more importantly, the mechanisms of resistance. For example, the activation of 
PARP 1 by Ras/Raf/Erk pathway has been observed.209  Thus, such combination may be of 
clinical relevance. PARP activity is at least in part responsible for HIF-1ǂ expression.208  
Building on the clinical benefit of anti-VEGFR TKI in soft tissue sarcoma, the combinations 
with PARP inhibitor have been initiated.  
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Protective effects of PARP inhibition on doxorubicin related cardiac toxicities210, platinum- 
and taxane related neurotoxicities211 and cisplatin-related nephrotoxicities212 without 
compromising anti-tumour activities have been reported in preclinical models. Careful 
study of the incidence of toxicity will be fruitful during clinical debelopment such as 
randomized phase II studies with toxicities as one of the main endpoints will be worthwhile.  
Apoptosis pathways 
Apoptosis, otherwise known as programmed cell death, is a critical process required for 
maintaining tissue homeostasis. Furthermore, it prevents tumorigenesis by eliminating 
damaged cells. Apoptosis occurs through two major pathways. The extrinsic or death 
receptor pathway is turned on in response to extracellular signals resulting in activation of 
plasma membrane receptors. This ultimately leads to processes that trigger initiator 
caspases which in turn activate executioner caspases.213  The intrinsic or mitochondrial 
pathway is turned on in response to a diverse set apoptotic signals which include DNA 
damage, growth factor withdrawal and viral infection. Mitochondria release co-factors from 
their intermembrane space which promote and amplify the apoptotic cascade including the 
formation and activation of apoptosomes.214  Although these pathways have their own 
distinct regulatory processes, there is also significant cross-talk in many situations.215  
Defects in apoptosis can lead to oncogenic transformation and contribute to therapeutic 
resistance.216   
Bcl-2 family 
The members of the Bcl-2 family of proteins are the key regulators of mitochondrial 
response to apoptotic signals and are divided into three subfamilies based on function and 
structure. The anti-apoptotic members include Bcl-2, Bcl-XL, Mcl-1, Bcl-w, and A1/Bfl1. The 
pro-apoptotic members include Bax and Bak. The third subfamily is the BH3-only group 
which is largely responsible for sensing apoptotic signals and transmitting them to the other 
Bcl-2 family members.217  Members of this subfamily include Bid, Bad, PUMA, and Noxa.214  
A network of interactions between these subfamilies decides the apoptotic fate of the cell 
and an imbalance within this network leads to a variety of disease states.  
The Bcl-2 family of proteins is a common target for deregulation in cancers. Anti-apoptotic 
members may be overexpressed or pro-apoptotic members may be mutated or silenced. 
These abnormalities have been demonstrated in soft tissue sarcomas. Bcl-2 overexpression 
has been demonstrated in synovial sarcoma, Kaposi’s sarcoma, solitary fibrous tumor and 
gastrointestinal stromal tumor (GIST).218,219  Focal positivity has been observed in both 
benign and malignant peripheral nerve sheath tumors. Sarcomas of fibroblastic type, 
including low-grade myxofibrosarcoma, malignant fibrous histiocytoma and fibrosarcoma 
showed variable expression of Bcl-2.218  The bcl-2 overexpression in synovial sarcoma 
include immunohistochemical expression of bcl-2, bax, bcl-x, and bac. Furthermore, this has 
been correlated with poor prognosis.220,221  
Oblimersen sodium (G3139, Genasense), the first agent targeting Bcl-2 to enter clinical trials, 
is a phosporothioate Bcl-2 antisense oligodeoxynucleotide that targets Bcl-2 mRNA. The cell 
death mechanisms of Bcl-2 antisense can be classified in two categories exerting either an 
apoptotic or a nonapoptotic effect based on their involvement in cell death pathways. Pre-
clinical data in combination with doxorubicin in the FU-SY-1 synovial sarcoma cell line 
enhanced doxorubicin-induced cell killin.222  Clinical development of oblimersen is 
unknown.  
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Similarly ABT 737 (A-779024, Abbott Laboratories), a small molecule that targets anti-
apoptotic Bcl-2 family proteins (Bcl-2, Bcl-XL, and Bcl-w), in combination with imatinib in 
GIST cell lines inhibits the proliferation and induces apoptosis in all GIST cell lines. Strong 
synergistic drug interactions at clinically relevant in vitro combinations were reported.223  
Clinical development of ABT-263 is ongoing in various solid tumours and chronic 
lymphocytic leukemia and in combination with other chemotherapeutic and targeted 
agents. ABT-263 is administered orally and thrombocytopenia is the dose-limiting and most 
common toxicity, which occurs on day 15 followed by a rebound by days 21-28 and due to 
mechanistic inhibition of Bcl-XL in mature platelets.224  Impressive anti-tumour activity has 
been observed in commonly Bcl-2 amplified chronic lymphocytic leukemia.225  SDs and a 
few PRs have been observed in solid tumours, including small-cell lung cancer which has 
overexpression of Bcl-2.224,226    
Many additional agents have been identified or designed to target the Bcl-2 family at the 
mRNA or protein level and pre-clinical data suggests these agents should be developed 
further in the subtypes of soft tissue sarcomas demonstrating Bcl-2 overexpression. 
Stem cell pathways 
The developmental pathways important to normal stem cells are also important to cancer 
stem cells (CSC). Like normal stem cells, CSC are thought to possess the capacity for 
unlimited self renewal through symmetric division, the ability to give rise to progeny cells 
through assymetric division, and an innate resistance to cytotoxic therapies.227,228  However 
where the process of differentiation initiated by the normal stem cell results in a specialized 
progeny that has no proliferative potential, te CSC gives rise to progeny that do not undergo 
terminal differentiation but instead exhibit uncontrolled proliferation.229   
Due to similarities to normal stem cells, CSCs are predicted to rely on the same pathways 
that govern development, self-renewal and cell fate. In embryonic stem cells, the Notch, 
Wnt, and Hedgehog (HH) pathways largely regulate these processes.230  These pathways are 
frequently dysregulated in many types of cancers, and specifically within subpopulations of 
these cancers that possess stem cell like properties (Li et al, 2010; Barker et al, 2006; 
Haegebarth et al, 2009; Wang et al, 2010).231-233 
Hedgehog (HH) pathway234 
Under normal conditions, HH signaling plays important roles in embryonic development 
tissue regeneration in adults (Ingham PW et al, 2001; Vajosalo M et al, 2008). HH signaling is 
comprised of multiple ligands that regulate receptor activity. HH signaling is initiated when 
one of three HH ligands (Sonic, Indian and Desert) bind the receptor Patched (Ptch1). The 
ligand/receptor interactions may be autocrine or paracrine. Receptor engagement results in 
activation of the transmembrane Smoothened (Smo), which is inactive state in the absence of 
a ligand. Subsequently, Smo activation regulates transcription of genes involved in HH 
signaling such as Gli1, Gli2 adn Gli3. Gli1/2/3 regulate the transcription of genes involved 
in HH signaling such as Gli1 and Ptch1 as well as genes involved in epithelial-mesenchymal 
transitin (EMT), such as SNAIL1.235   
Dysregulation of nearly every step of the HH signaling pathway has been linked to cancer 
development and progression. In rhabdomyosarcoma (RMS), the most common soft tissue 
sarcoma in children, HH signaling is preferentially activated in specific subgroups of 
RMS.236-239  Ptch1, Gli1, and Gli3 are expressed at significant higher levels in embryonal RMS 
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than in fusion-gene negative alveolar RMS than in fusion-gene positive alveolar RMS. High 
expression of Ptch1 significantly correlated with reduced cumulative survival.238   
Betullinic acid possesses anti-tumoral acivity and overcomes resistance by inducing 
apoptosis in a variety of human cancers.240  In preclinical study using RMS-13 cells, which is 
known to display an activate HH pathway caused by DNA amplification of the Gli1 locus, 
betullinic acid effectively suppressed HH target gene expression.238   
Early phase clinical trials are underway which include patients with soft tissue sarcomas 
with agents such as GDC 0449 (Genetech),241-244 LDE225 (Novartis Pharmaceuticals)245 and 
BMS-833923246 which both selectively inhibit Smo. Preliminary anti-tumour activity in 
consistently in basal cell carcinoma and medulloblastoma and in sporadiac cases of non-
small cell lung cancer. All are orally administered on a daily schedule. Only IPI-926 is a 
cyclopamine analogue that is administered intravenously.247 Toxicity includes 
gastrointestinal (nausea, vomiting), anorexia, muscle spasm/cramps, fatigue and dysguesia. 
Due to the long half-life of days, various alternative dosing schedules are being tested to 
optimize toxicity and anti-tumour activity. Combination with various chemotherapy and 
targeted agents are ongoing, such as PI3K inhibitor.  
Notch signaling pathway 
The Notch pathway is a highly conserved regulatory signaling network with the basic 
molecular players in the pathway including 5 ligands (Dll 1, 3, 4 and Jagged 1, 2), Notch 
receptors (Notch 1 to Notch 4) and the transcription factors. A complex signaling pathway is 
initiated when a ligand expressed on one cell engages a receptor expressed on another cell. 
Upon ligand/receptor interaction a cleavage event removes the Notch/ligand complex from 
the membrane bound portion of Notch. The cytoplasmic region of Notch then undergoes a 
proteolytic cleavage mediated by -secretase, releasing an intracellular domain peptide 
which translocates to the nucleus and drives transcription of Notch target genes.230  The 
physiologic functions of Notch signaling are multifaceted and include maintenance of stem 
cells, specification of cell fate, and regulation of differentiation in development as well as 
oncogenesis.248,249 
-secretase inhibitors are a promising therapeutic approach as they act downstream of the 
ligand/receptor interactions and therefore should not be affected by the diversity of ligands, 
receptors and combinations thereof. Currently several -secretase inhibitors are being 
evaluated in early Phase human studies. 
Aberrant Notch signaling has been reported in rhabdomyosarcoma and Kaposi sarcoma cell 
lines.250,251  A striking increase in Notch 2 expression was observed. In addition a slight 
upregulation of Notch 3 was also noted. However, Notch 1 and 4 were not significantly 
increased. Increased expression of two downstream effectors, Hes1 and Hey1, correlated 
with invasiveness of the cell lines. The addition of -secretase inhibitors significantly 
decreased the Hes1 and Hey1 expression. Furthermore, with addition of -secretase 
inhibitors, a significant reduction in cell mobility was observed suggesting the Notch 
pathway may play a role in the invasiveness of the cell lines.250  In pre-clinical studies, a -
secretase inhibitor also blocked Notch activation and induces apoptosis in Kaposi's sarcoma 
tumor cells.251  These findings show that the Notch pathway is important in regulating these 
subtypes of soft tissue sarcoma and may -secretase inhibitors be useful therapeutic agents. 
Wnt pathway 
Wnts are secreted glycoproteins that bind to cell surface receptors initiating signaling 
cascades which are important in many physiologic settings including embryogenesis, 
www.intechopen.com
 
Novel Therapeutic Targets in Soft Tissue Sarcomas 
 
235 
development, cell polarization, differentiation and proliferation .252-256  The Wnt signaling 
pathways fall into two categories: canonical and non-canonical, characterized by their 
dependence on -catenin. Canonical Wnt will be the focus of this section as it is better 
characterized in mammalian systems. Canonical Wnt signaling is initiated when a Wnt 
ligand engages co-receptors of the Frizzled (Fzd) and low-density lipoprotein receptor-
related protein (LRP) families, leading to -catenin stabilization, nuclear translocation and 
activation of target genes.230,257 
The relevance of Wnt signaling in human cancers is highlighted by the frequency of which 
this pathway is aberrantly activated across a vast range of malignancies. There are 
numerous mechanisms that drive aberrant Wnt/-catenin signaling than nearly always 
occur in a mutually exclusive manner. In one study, 50% of human sarcomas and 65% of 
sarcoma cell lines of diverse histological subtypes exhibit upregulated autocrine canonical 
Wnt signaling. Furthermore, in Wnt autocrine cell lines, alterations included overexpression 
or gene amplification of Wnt ligands and/or LRP5/6 coreceptors and epigenetic silencing of 
different cell surface Wnt antagonists.258  High level of nuclear expression of -catenin has 
reported in solitary fibrous tumor, endometrial stromal sarcoma, synovial sarcoma, 
dedifferentiated liposarcoma, and malignant fibrous histiocytoma.259-262 
There are three major areas of targeting the Wnt pathway which include receptor/ligand 
interactions, cytosolic signaling components, and nuclear signaling components. In pre-
clinical studies, monoclonal antibodies against Wnt1 induced apoptosis in a number of cell 
lines including sarcoma.263,264  In vitro results are encouraging and warrant further 
development. An alternate approach to inhibiting ligand/receptor interactions would be to 
target the Wnt co-receptors. The LRP family is comprised of 2 highly homologous members, 
LRP5 and LRP6 which are long single- pass transmembrane receptors which could be 
targeted through antibodies.265  The Fzd family of transmembrane receptors also shares a 
high degree of homology in their cysteine rich domain which could be targeted through an 
antibody to block Wnt signaling.266   
Targeting the cytosolic signaling components of the Wnt pathway are in preclinical or phase 
I early development. No clinical information is currently available. The small molecules in 
development include those targeting Dvl, Tankyrase1 and 2, Axin, Porcupine, and -
catenin.230  Similarly nuclear signaling small molecules which would interrupt the -catenin 
interaction with TCF/LEF are also in early development. 
6. Conclusions 
With decades of research into the biology of each target, its interaction with other pathways 
or targets, and the relevance in sarcoma, it is an exciting time in drug development in soft 
tissue sarcomas. But the academia and industry must remember that soft tissue sarcoma is a 
collective term for a florid of many different diseases, though some share similar 
characteristics, such as the translocation associated sarcomas and their fusion proteins with 
transcription factor activity, each target may only be relevant to a small number of subtypes. 
A lot of investment and time will be needed in order to bring these agents to the market 
with a small return. 
During the development of these agents, it is important to understand the biology of these 
targets and their effects on the sarcoma cells, cytostatic or cytotoxic, as it will influence the 
clinical endpoints, progression-free survival or progression-free rate versus response rate, 
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respectively, in proof of concept phase II studies. This approach will lessen our chance of 
failure in the phase III setting. 
Furthermore, how can a target, expression/overexpression, amplification, mutation, or 
translocation, be considered to be of clinical relevance for clinical therapeutics?  There seems 
to be a different answer for different cancer. Therefore, detail preclinical modeling and 
translational research using archival tumour samples will be important. It is important to 
collect tumour (fresh biopsies before and after therapy and archival samples), blood or even 
urine samples during proof of concept studies in order to validate the target identify and to 
evaluate novel predictive markers for clinical benefit.  
Resistance is universal for any cancer therapeutics. Preclinical, translational and clinical 
research should be done to elucidate these escape mechanisms. Such information can help 
us not only to develop combinatorial therapeutics to delay or prevent resistance and thus 
more prolonged clinical benefits, but also to understand the biology of sarcomas and thus 
new therapeutic options when resistance emerges.  
With the constant quest of the sarcoma community to understand and to develop new 
agents for this vastly diverse cancer, it is the hope that more effective and less toxic agents 
will be available for the treatment of this disease.  
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